About this trial
A fully functional brown fat helps maintain a healthy weight and decreases the risk of metabolic diseases such as type II diabetes (T2DM). Unfortunately, in human adults, the functionality of brown fat declines with age, and it is one of the reasons for gaining unhealthy weight, particularly around the waistline (central obesity). Currently, scientists do not clearly understand the reasons for the decline in brown fat functionality. It is possible that the decline in the availability of the molecule Nicotinamide Adenine Dinucleotide (NAD+), which is central to several metabolic processes, plays a role in the decline in brown fat metabolism. This project will clarify whether NAD+-based molecular-targeted therapies for the enhancement of whole-body insulin sensitivity and brown fat metabolism will be successful in adult humans, which will eventually be an important target for reducing the development of obesity and its comorbidities such as T2DM.
Eligibility criteria
Qualifiers
Willingness to provide informed consent to participate in the BATNAD study
Must be able to read and speak English/Finnish/Swedish well enough to completely understand the instructions and provide informed consent
Age 30-55 (sedentary lifestyle)
BMI = 18-25 kg/m2 (normal-weight subjects)
Disqualifiers
Inability to have PET/CT (claustrophobia, metal implants, recent tattoo including metal components, weight > 200 kg)
Pregnancy and pregnancy related conditions (postpartum/lactation during the last 12 months, or planning to become pregnant soon)
Major alterations in the menstrual cycle (e.g., amenorrhea)
Use of nicotine based products
Trial design
Treatments tested in this trial
- NAD+ precursor
- Placebo